PCN31 Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment for Patients with HER2-Positive EARLY Breast Cancer: Update Results after National Drug Reimbursement LIST Adjustment in China

MLA

C.F. Hao, et al. “PCN31 Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment for Patients with HER2-Positive EARLY Breast Cancer: Update Results after National Drug Reimbursement LIST Adjustment in China.” Value in Health Regional Issues, vol. 22, Sept. 2020, p. S10. EBSCOhost, https://doi.org/10.1016/j.vhri.2020.07.081.

APA

C.F. Hao, Y.S. Wang, Hongchao Li, Q. Yang, Q.J. Chen, Jiming Zhang, J.J. Li, C. Liu, X. Guan, Hanmei Xu, & A.X. Ma. (2020). PCN31 Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment for Patients with HER2-Positive EARLY Breast Cancer: Update Results after National Drug Reimbursement LIST Adjustment in China. Value in Health Regional Issues, 22, S10. https://doi.org/10.1016/j.vhri.2020.07.081

Chicago

C.F. Hao, Y.S. Wang, Hongchao Li, Q. Yang, Q.J. Chen, Jiming Zhang, J.J. Li, et al. 2020. “PCN31 Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment for Patients with HER2-Positive EARLY Breast Cancer: Update Results after National Drug Reimbursement LIST Adjustment in China.” Value in Health Regional Issues 22 (September): S10. doi:10.1016/j.vhri.2020.07.081.